News | September 23, 2022
U.S. District Court rules in favor of Merck in Sitagliptin Phosphate patent lawsuit
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
The two generic drugs have been launched under the brand names Jankey & Sitenali.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Key takeaways of Q3FY22 quarter & conference call highlights
The start-up has announced the scheme to mark World Diabetes Day
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Subscribe To Our Newsletter & Stay Updated
